SLC5A2 and type 2 diabetes mellitus: If SGLT2 inhibitors attenuate renal glucose reabsorption in renal tubules, glucotoxicity in tubular cells and glucose-mediated local RAS activation in the kidney would be attenuated in type 2 diabetes.